Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00003054|
Recruitment Status : Terminated
First Posted : June 25, 2003
Last Update Posted : April 12, 2018
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with recurrent or persistent cancer of the uterus.
|Condition or disease||Intervention/treatment||Phase|
|Sarcoma||Drug: paclitaxel||Phase 2|
OBJECTIVES: I. Estimate the antitumor activity of paclitaxel in patients with metastatic or persistent leiomyosarcoma of the uterus who have failed treatment protocols of higher priority. II. Determine the nature and degree of toxic effects of paclitaxel in this group of patients.
OUTLINE: Patients receive a continuous infusion of paclitaxel once every 3 weeks over 3 hours. Patients in complete remission, partial remission, or stable disease undergo at least 3 courses of paclitaxel. Paclitaxel continues until disease progression or adverse effects prohibit further treatment. All patients are followed until death.
PROJECTED ACCRUAL: This study anticipates an annual accrual of approximately 25 patients over 2.5 years.
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus|
|Study Start Date :||August 1997|
|Actual Primary Completion Date :||July 2002|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00003054
Show 65 Study Locations
|Study Chair:||Donald G. Gallup, MD||Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center|